International Brand Name:
In treatment of:
Treatment of disorders associated w// decreased GI motility
1.Hypersensitivity to Mosapride
Mosapride`s major degradation system is the cytochrome P450 (3A4) system. However, electrophysiological studies show that coadministration of drugs that inhibit the CYP 3A4 enzymes (erythromycin, ketoconazole, fluconazole, etc.) have no effect on mosapride indicating that a satisfactory safety margin exists in relation to rhythm abnormalities, unlike that which occurs with cisapride.
Oral:2.5 - 10 mg every 6 - 8 hours in a day with meals